Neurogene Inc. short interest in 2022
In 2022, Neurogene Inc.'s disclosed short interest ran from 2.20% of shares outstanding on 14 Jan 2022 to 0.65% on 30 Dec 2022, a change of -1.55 percentage points. The year's high was 5.27% on 31 May 2022 and its low 0.65% on 30 Dec 2022, averaging 2.54% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 10.97 days on 31 May 2022. Full history: Neurogene Inc..
Cite this page
By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2022 in figures
- Start of year
- 2.20% (14 Jan 2022)
- End of year
- 0.65% (30 Dec 2022)
- Change
- -1.55 pp
- High
- 5.27% (31 May 2022)
- Low
- 0.65% (30 Dec 2022)
- Average
- 2.54%
- Highest days to cover
- 10.97 (31 May 2022)
- SEC filings marked
- 8
Every report in 2022
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 14 Jan 2022 | 2.20% | 4.16 | |
| 31 Jan 2022 | 2.71% | 4.66 | |
| 15 Feb 2022 | 2.97% | 5.58 | |
| 28 Feb 2022 | 3.19% | 9.18 | |
| 15 Mar 2022 | 3.28% | 6.46 | 10-K filed, results (8-K) |
| 31 Mar 2022 | 3.57% | 5.26 | |
| 14 Apr 2022 | 3.64% | 3.53 | |
| 29 Apr 2022 | 4.47% | 7.03 | |
| 13 May 2022 | 4.97% | 6.12 | 10-Q filed, results (8-K) |
| 31 May 2022 | 5.27% | 10.97 | |
| 15 Jun 2022 | 5.25% | 6.64 | |
| 30 Jun 2022 | 2.50% | 1.52 | |
| 15 Jul 2022 | 2.43% | 5.19 | |
| 29 Jul 2022 | 2.28% | 7.24 | |
| 15 Aug 2022 | 2.67% | 1.67 | 10-Q filed, results (8-K) |
| 31 Aug 2022 | 1.73% | 4.13 | |
| 15 Sep 2022 | 1.26% | 3.88 | |
| 30 Sep 2022 | 0.88% | 2.48 | |
| 14 Oct 2022 | 0.83% | 4.92 | |
| 31 Oct 2022 | 0.92% | 3.62 | |
| 15 Nov 2022 | 1.11% | 1.46 | 10-Q filed, results (8-K) |
| 30 Nov 2022 | 1.28% | 2.00 | |
| 15 Dec 2022 | 0.94% | 2.48 | |
| 30 Dec 2022 | 0.65% | 1.00 |
See also: Neurogene Inc.'s full history · most shorted US stocks of 2022 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.